Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer.

被引：0
|
作者：
Griggs, JJ [1 ]
Schiffhauer, LM [1 ]
Sahasrabudhe, DM [1 ]
Pandya, KJ [1 ]
Caldwell, C [1 ]
Peacock, J [1 ]
Messina, P [1 ]
Spreng, E [1 ]
Bourne, P [1 ]
McGuire, GM [1 ]
机构：
[1] Univ Rochester, Rochester, NY 14627 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76S / 76S
页数：1
相关论文
共 50 条
  • [21] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
    Ueno, Takayuki
    Masuda, Norikazu
    Sato, Nobuaki
    Ohtani, Shoichiro
    Yamamura, Jun
    Matsunami, Nobuki
    Kashiwaba, Masahiro
    Takano, Toshimi
    Takahashi, Masato
    Kaneko, Koji
    Ohno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (01) : 3 - 11
  • [23] HER-2 positive breast cancer and trastuzumab: lessons learnt by heart
    Outhoff, k
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 1 (02) : 52 - 57
  • [24] Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab
    Bachir, B.
    Anouti, S.
    Jaoude, J. Abi
    Kayali, M.
    Tfayli, A.
    De Azambuja, E.
    Poortmans, P.
    Zeidan, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S7 - S7
  • [25] HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
    Widakowich, Christian
    Dinh, Phuong
    de Azambuja, Evandro
    Awada, Ahmad
    Piccart-Gebhart, Martine
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (05) : 488 - 496
  • [26] Concomitant Radiation Therapy is Associated With Persistent Declines in Ejection Fraction After Adjuvant Trastuzumab for HER-2 Positive Breast Cancer.
    Andersen, Mousumi M.
    Ayala-Peacock, Diandra
    Bowers, Jessie
    Kooken, Banks
    D'Agostino, Ralph B.
    Jordan, Jennifer H.
    Vasu, Sujethra
    Thomas, Alexandra
    Klepin, Heidi
    Brown, Doris R.
    Hundley, William G.
    CIRCULATION, 2018, 138
  • [27] Analysis of drug resistance in HER-2 positive breast cancer.
    Lerma, N.
    Valenzuela, P.
    Parra, K.
    Becerril, C. L.
    Miramontes, I.
    Ramirez, E.
    Rodriguez, C.
    Francia, G.
    MOLECULAR BIOLOGY OF THE CELL, 2012, 23
  • [28] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [29] Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer
    Ferretti, Gianluigi
    Papaldo, Paola
    Fabi, Alessandra
    Carlini, Paolo
    Felici, Alessandra
    Cognetti, Francesco
    ONCOLOGIST, 2006, 11 (07): : 853 - 854
  • [30] Recent trends of HER-2 testing and trastuzumab therapy for breast cancer
    Masafumi Kurosumi
    Breast Cancer, 2009, 16 : 284 - 287
12345